Funding Will Support Investigational Device Exemption for Concept Medical's Sirolimus-Coated Balloon

 

October 9, 2018—Concept Medical Inc. (CMI) announced that it is seeking an FDA investigational device exemption (IDE) to conduct a clinical study of the safety and effectiveness of the company's MagicTouch-DEB, a sirolimus-coated balloon with application in coronary and peripheral artery disease.

The company has raised $60 million to fund the support the process. The funds were provided by cardiologist and entrepreneur Kiran Patel, MD, of Tampa, Florida. Dr. Patel is the Founder and Chairman of the Drs. Kiran and Pallavi Patel Family Foundation.

The funds will also be used to augment clinical data and clinical registries to qualify for reimbursement in the European markets, where CMI has commercially launched the sirolimus-coated balloon. A portion of the funds will also be used to bolster the company's manufacturing operations.

The company has globally commercialized its first product, the coronary Abluminus-DES drug-eluting stent. The MagicTouch-DEB is commercially sold in Europe and other international markets.

CMI is headquartered in Florida with a subsidiary in India, Envision Scientific Pvt. Ltd., where all their products are manufactured. Global distribution and marketing network are operated from offices in India, Singapore, Netherlands, and Brazil.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.